VEGFA and retinal vein occlusion: For all indications, the BCVA of the study eye showed improvement over time, with highest gains observed after twelve months of anti-VEGF therapy for patients with retinal vein occlusions (nAMD, +3.1 letters; DME, +5.0 letters; BRVO, +13.5 letters; CRVO, +12.8 letters, Figure 2A).